AzTrials
AzTrials

Depressive SymptomsPhase 2JAK DC in PlayNCT07608796

JAK Signaling in Depression and Cognition in Male Football Players

A Phase 2 study testing Baricitinib in people with Depressive Symptoms and Cognitive Symptom, run by Emory University at 3 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

This study is being done to learn more about the role of inflammation in depressive and cognitive symptoms in patients with depression who have played at least 11 years of organized tackle football. This will be evaluated using a medication called baricitinib, which blocks one aspect of inflammation. Read more about this study

Who is it for?
Ages 30 to 55 years, men onlyHealthy volunteers can take part
Conditions the study is for
Depressive Symptoms, Cognitive Symptom
What is being tested?
Baricitinib
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
3 sitesUnited States
Study dates
Oct 2026to Oct 2027
Phase
Phase 2

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 55 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • willing and able to give written informed consent
  • males
  • playing tackle football for at least 11 years
  • 30-55 years of age
  • Current Diagnostic and Statistical Manual (DSM)-V major depression or Bipolar, depressed type; or DSM-V major depression or Bipolar, depressed type in partial remission as diagnosed by the Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders (SCID)-V
  • score of >10 on the PHQ-9 from screening and HAM-D score ≥16 for study entry
Show all 9Show fewer
  • off all antidepressant or other psychotropic therapy (e.g., mood stabilizers, antipsychotics, and sedative hypnotics) for at least 4 weeks before baseline visit (8 weeks for fluoxetine) or on a stable psychotropic regimen for at least 4 weeks (and no planned changes)
  • CRP ≥3 mg/L
  • PHQ-9 anhedonia (item #1) and cognitive (item #7) scores ≥2

Who cannot join

  • current or history of past autoimmune disorder
  • history or evidence (clinical or laboratory) of hepatitis B or C infection or human immunodeficiency virus infection
  • history of any type of cancer requiring treatment with more than minor surgery
  • unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination, EKG, and laboratory testing)
  • significant hematological abnormalities at screening (ANC < 1500, Hgb<10, platelet< 100,000)
  • history of progressive multifocal leukoencephalopathy
Show all 14Show fewer
  • history of deep venous thrombosis
  • history of cardiovascular disease (coronary artery disease, congestive heart failure, stroke - controlled hypertension is OK)
  • major surgery within 6 months before screening, or will require major surgery during the study
  • current or recent (<4 weeks before study start) viral (including COVID-19), bacterial, fungal, or parasitic infection, or any other active or recent infection
  • symptomatic herpes zoster infection at or within 12 weeks of study start
  • history of disseminated/complicated herpes zoster (for example, ophthalmic zoster or CNS involvement)
  • cirrhosis of the liver from any cause
  • Additional exclusion criteria apply

Trial locations and contacts

3 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Andrew H Miller, MD contact

404-727-8260

amill02@emory.edu

United States3 sites, 3 recruiting
  • Emory Clinic, Emory University Hospital

    Atlanta, Georgia, 30322

    Andrew Miller, MD

    Recruiting
  • Emory School Of Medicine

    Atlanta, Georgia, 30322

    Recruiting
  • Emory University

    Atlanta, Georgia, 30329

    Recruiting

Other trials in United States

About this study

This study is being done to learn more about the role of inflammation in depressive and cognitive symptoms in patients with depression who have played at least 11 years of organized tackle football. This will be evaluated using a medication called baricitinib, which blocks one aspect of inflammation.

Read the detailed description

This study is being done to learn more about the role of inflammation in depressive and cognitive symptoms in patients with depression who have played at least 10 years of football. This will be assessed using a medication called baricitinib that blocks one aspect of inflammation.

This study will enroll depressed adult male football players enriched for high inflammation [blood levels of C-reactive protein (CRP)], anhedonia, and cognitive dysfunction.

Qualifying participants will be asked to take the study medication once daily by mouth for 8 weeks and undergo MRI scans, provide blood and urine samples for safety or to measure biomarkers of inflammation, complete clinician-rated and self-report assessments of depressive and cognitive symptoms, and perform computer or paper-and-pencil tests of neurocognitive function. Blood and other biological samples may be stored for future research use, with the participant's consent.

Being tested
Baricitinib
Keywords
Football player, Inflammation, NFL
Medical subject headings
Depression, Neurobehavioral Manifestations, Inflammation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BaricitinibDrug

    Also called Olumiant

    Baricitinib is an orally administered, selective inhibitor of Janus kinase (JAK) 1 and 2. It reduces cytokine-mediated signaling involved in inflammation and immune activation. Baricitinib is FDA-approved for rheumatoid arthritis (RA), atopic dermatitis, and alopecia areata. It has also been authorized for the treatment of COVID-19 in hospitalized patients. Baricitinib will be dispensed every other week at the Week 2, 4, and 6 study visits. Participants who do not exhibit a clinical response (50% reduction in HAM-D scores from baseline) at Week 4 will be increased to 4 mg/day of baricitinib (2 x 2 mg tablets). A virtual follow-up visit will be conducted at Week 1 to assess safety and tolerability in all patients, and at Week 5 in patients who increase the dose.

Study groups in NCT07608796
Study groupRoleWhat they receive
BaricitinibExperimentalParticipants will receive 1 tablet/d of 2 mg baricitinib at baseline. For participants who do not exhibit a clinical response at 4 Weeks (a 50% reduction in HAM-D scores), the dose will be increased to 4 mg/day (2 tablets/d of baricitinib), as tolerated.
Receives: Drug: Baricitinib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Monetary Incentive Delay (MID) Task functional magnetic resonance imaging (fMRI)

    Resting-state and task-based MID Task functional magnetic resonance imaging (fMRI). The MID Task is a specialized behavioral paradigm used during functional magnetic resonance imaging (fMRI). It isolates and measures the neural mechanisms of reward processing, specifically motivational salience, anticipation, and outcome feedback. fMRI blood oxygen level-dependent (BOLD) for resting and task-based functional connectivity: A multi-echo (ME) ep2 BOLD sequence will be optimized to provide a high signal-to-noise ratio in regions of interest that is maintained during minor incidences of head motion. Resting ME BOLD will be acquired over ~10 min, and task fMRI will involve two ~10 min scans. For resting bold, a single acquisition of phase-encoding in the opposite polarity (anterior-posterior) for distortion correction over ~30 seconds.

    Measured: Baseline and weeks 2 and 8 post-intervention

Secondary outcomes (11)
  1. Effort-Expenditure for Rewards Task (EEFRT)

    The EEfRT is a widely used, multi-trial task measuring motivation for rewards as an assessment of anhedonia, as anhedonia is specifically associated with decreased motivation for rewards.

    Participants are given an opportunity to choose between two different task difficulty levels in order to obtain monetary rewards by repeated manual button presses within a short time. Button presses raise a virtual ''bar'' viewed onscreen. If they raise the bar to the ''top'' within the prescribed time, they are eligible to win the allotted money. Each trial presents the subject with a choice between two levels of task difficulty, a 'hard task' and an 'easy task,' and 3 probabilities of winning. Subjects participate in the task for 20 minutes, and the first 50 trials are analyzed by calculating the proportion of hard-task choices across each level of probability. Lower proportions of hard task choices indicate decreased motivation.

    Measured: Baseline and weeks 2, 4 and 8 post-intervention

  2. Finger Tapping Test (FTT)

    The Finger Tapping Test (FTT) is a simple neuropsychological assessment that measures fine motor speed, coordination, and nervous system health. This task uses a specially adapted tapper that the subject is asked to tap as fast as possible using the index finger. The subject is given 5 consecutive 10-second trials for both the preferred and non-preferred hands. The finger tapping score is the mean of the 5 trials and is computed for each hand.

    Normal/Average: 45-60 taps. Mild Slowing / Potential Impairment: 30-45 taps. Significant Motor Impairment / Fatigue: Fewer than 30 taps

    Measured: Baseline and weeks 2, 4 and 8 post-intervention

  3. Trail-Making Test (TMT)

    The Trail-Making Test (TMT) is a common neuropsychological assessment measuring processing speed, visual attention, and task-switching ability. The test is typically administered using a paper-and-pencil format (or digital equivalent) and has two primary sections: Part A: Patients connect 25 randomly distributed circles containing numbers in ascending order (1, 2, 3...) as quickly as possible. This measures baseline processing speed, motor speed, and visual scanning. Part B: Patients connect 25 circles containing both numbers and letters, strictly alternating between them in ascending order (1-A-2-B-3-C...). This places a much higher cognitive demand on mental flexibility, set-shifting, and working memory. Evaluators record the total time (in seconds) taken to complete each part. Longer times generally indicate poorer cognitive function.

    Measured: Baseline and weeks 2, 4 and 8 after baricitinib started

  4. Anhedonia Subscale of the Inventory of Depressive Symptoms-Self Reported (IDSSR)

    Anhedonia is assessed with a 3-item subscale of the Inventory of Depressive Symptomatology Self-Report (IDS-SR). Each of the three items is rated on a 4-point severity scale from 0 to 3, where 0 indicates no impairment, and 3 indicates maximum severity. Scores range from 0 to 9, with higher scores reflecting a greater severity of anhedonia, meaning a stronger loss of interest, motivation, and ability to experience pleasure.

    Measured: Baseline and weeks 2, 4, 6, and 8 post-intervention

  5. Behavior Rating Inventory of Executive Function, Second Edition (BRIEF2A)

    BRIEF2A is a standardized rating scale that allows adults and knowledgeable informants (caregivers, adult children, partners/spouses) to rate executive function or self-regulation in that adult's day-to-day setting. Scoring relies on T-scores (Mean = 50, Standard Deviation = 10).

    < 60 T-score: Within Normal Limits. 60 - 64 T-score: Subclinical difficulties; subtle but generally manageable challenges.

    65 - 69 T-score: Mildly elevated; noticeable executive function deficits. 70 - 74 T-score: Moderately elevated; significant executive dysfunction affecting daily life.

    >= 75 T-score: Highly elevated; severe impairment.

    Measured: Baseline and weeks 2 and 8 post-intervention

  6. Snaith-Hamilton Pleasure Scale-Clinician (SHAPS-C)

    The Snaith-Hamilton Pleasure Scale-Clinician (SHAPS-C) is a 14-item validated clinician-administered assessment tool used to measure hedonic capacity and evaluate anhedonia (the inability to experience pleasure). The clinician asks the patient about their expected or actual ability to feel pleasure over the past few days, translating the standard self-report questions into a guided clinical interview. Responses are typically evaluated using a 4-point Likert scale (Strongly Disagree, Disagree, Agree, Strongly Agree). Total scores range from 0 to 14, with higher scores indicating greater difficulty experiencing pleasure or a higher level of anhedonia.

    Measured: Baseline and weeks 2, 4, 5, 6, and 8 after baricitinib started

  7. Hamilton Depression (HAM-D) Rating Scale

    Hamilton Depression (HAM-D) Rating Scale is the most widely used clinician-administered depression assessment scale. It evaluates symptoms such as mood, guilt, insomnia, anxiety, and weight loss over the previous week.

    Scores are tallied to estimate the severity of the depression, although context and clinical judgment are always required. Maximum score is 52 0 to 7: Normal/Remission 8 to 16: Mild Depression 17 to 23: Moderate Depression 24 or higher: Severe Depression

    Measured: Baseline and weeks 2, 4, 5, 6, and 8 post-intervention

  8. Columbia Suicide Severity Rating Scale (CSSR)

    The Columbia-Suicide Severity Rating Scale (C-SSRS) evaluates both suicidal ideation and suicidal behavior.

    Minimum 0 (no ideation) to Max: 5 (active suicidal ideation with a specific plan and intent).

    Meaning of Scores:0: No suicidal ideation reported.

    1. (Wish to be Dead): Endorses thoughts about a wish to be dead or not alive.
    2. (Non-Specific Thoughts): General, non-specific thoughts of wanting to end life, without methods or plans.
    3. (Method, No Intent/Plan): Thoughts of suicide with a specific method in mind, but no intent or actual plan to act.
    4. (Some Intent, No Plan): Thoughts of suicide and some intent to act, but without fully mapped-out details.
    5. (Specific Plan and Intent): Fully or partially worked-out details of a suicide plan with intent to carry it out.

    Measured: Baseline and weeks 2, 4, 5, 6, and 8 post-intervention

  9. Phosphorylated Signal Transducer and Activator of Transcription 3 (pSTAT3)

    Intracellular pSTAT3 in peripheral blood immune cells will be assessed by flow cytometric methods.

    Measured: Baseline and weeks 2 and 8 post-intervention

  10. Inflammatory cytokines (IL-1, IL-6, TNF)

    IL-1, IL-6, TNF and their soluble receptors will be analyzed by multiplex bead-based assays, previously validated against individual ELISA.

    Measured: Baseline and weeks 2 and 8 post-intervention

  11. High-sensitivity (hs) CRP

    High-sensitivity (hs) CRP will be assayed using an immunoturbidometric assay with a Beckman AU480 chemistry analyzer and Ultra WR CRP kit (Sekisui Diagnostics).

    Measured: Baseline and weeks 2 and 8 post-intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 May 2026
  2. Study startOct 2026 (estimated)
  3. Primary completionOct 2027 (estimated)
  4. Study completionOct 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07608796
Sponsor's protocol ID
2026P000577
Acronym
JAK DC in Play
Status last verified
Sep 2026
First submitted
20 May 2026
Last updated
24 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in